Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Now is no time to add pressure on businesses: top executives

    Now is no time to add pressure on businesses: top executives
  2. 2

    CJ CheilJedang to spur overseas growth with new Hungary, US plants

    CJ CheilJedang to spur overseas growth with new Hungary, US plants
  3. 3

    Seoul to host winter festival from Dec. 13

    Seoul to host winter festival from Dec. 13
  4. 4

    Nationwide rail disruptions feared as union plans strike from Dec. 5

    Nationwide rail disruptions feared as union plans strike from Dec. 5
  5. 5

    Blackpink's solo journeys: Complementary paths, not competition

    Blackpink's solo journeys: Complementary paths, not competition
  1. 6

    N. Korea, Russia court softer image: From animal diplomacy to tourism

    N. Korea, Russia court softer image: From animal diplomacy to tourism
  2. 7

    Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid

    Smugglers caught disguising 230 tons of Chinese black beans as diesel exhaust fluid
  3. 8

    [Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts

    [Today’s K-pop] Blackpink’s Jennie, Lisa invited to Coachella as solo acts
  4. 9

    Actor Song Joong-ki welcomes second child in Rome

    Actor Song Joong-ki welcomes second child in Rome
  5. 10

    Main opposition pushes to ease, not postpone, tax on crypto gains

    Main opposition pushes to ease, not postpone, tax on crypto gains
지나쌤

Hanmi Pharmaceutical’s operating profit forecast to expand fourfold in Q2

By 안성미

Published : July 11, 2016 - 17:32

    • Link copied

[THE INVESTOR] Hanmi Pharmaceutical’s second-quarter operating profit is projected to grow significantly, while sales will likely suffer a decline, industry data showed on July 11.

According to a market data provider FnGuide, Hanmi’s operating profit is expected to grow fourfold in the second quarter on-year to 10.8 billion won (US$ 9.4 million). However, sales will fall 3.56 percent to 235 billion won.

Analysts say lower-than-expected growth from Hanmi subsidiaries such as Beijing Hanmi and Hanmi Fine Chemical will cause the profit decline. 

Hanmi Pharmaceutical Hanmi Pharmaceutical


“Due to China’s overall markdown in drugs, Beijing Hanmi has yet to see increased sales,” said Kwak Jin-hee, analyst of Eugene Investment & Securities.

Projections for Hanmi were in contrast with those for its rivals Yuhan and Green Cross.

Yuhan’s operating profit is forecast to see a 2.34 percent decline to 25 billion won, while sales will stand at 306 billion won on the back of a 12.58 percent increase.

Green Cross’ operating profit is expected to fall 10.6 percent to 27 billion won, while sales will rise nearly 13 percent to 304 billion won.

By Ahn Sung-mi (sahn@heraldcorp.com)

More from Headlines